Increasing recent evidence has implicated osteoporosis as a risk factor for benign paroxysmal positional vertigo (BPPV). We conducted a systematic review to examine the association between osteoporosis and BPPV.
Background: Different types of medications are currently used in vestibular migraine (VM) prophylaxis, although recommendations for use are generally based on expert opinion rather than on solid data from randomized trials. We evaluated the efficacy and safety of venlafaxine , flunarizine and valproic acid in a randomized comparison trial for VM prophylaxis. Methods: Subjects were randomly allocated to one of three groups (venlafaxine group, flunarizine group, and valproic acid group). To assess the efficacy of treatment on vertigo symptoms, the following parameters were assessed at baseline and 3 months after treatment: Dizziness Handicap Inventory (DHI) scores, number of vertiginous attacks in the previous month, and Vertigo Severity Score. Adverse events also were evaluated. Results: A decrease in DHI total scores was shown following treatment with all three medications, with no obvious differences between the groups. Treatment effects differed, however, in the DHI physical, functional, and emotional domains with only venlafaxine showing a decreased effect in all of three domains. Flunarizine and valproic acid showed an effect in only one DHI domain. Venlafaxine and flunarizine showed decreased VSS scores (p=0 and p=0.03, respectively). Although valproic acid had no obvious effect on VSS (p=0.27), decreased vertigo attack frequency was observed in this group (p=0). Venlafaxine also had an effect on vertigo attack frequency (p=0) but flunarizine had no obvious effect (p=0.06). No serious adverse events were reported in the three groups. Conclusions: Our data confirm the efficacy and safety of venlafaxine, flunarizine and valproic acid in the prophylaxis of VM, venlafaxine had an advantage in terms of emotional domains. Venlafaxine and valproic acid also was shown to be preferable to flunarizine in decreasing the number of vertiginous attacks, but valproic acid was shown to be less effective than venlafaxine and flunarizine to decrease vertigo severity.
25 October 2014 in European Archives of Oto-Rhino-Laryngology
This study aimed to investigate the value of the surgery of revised uvulopalatopharyngoplasty (UPPP) on ambulatory blood pressure (BP) in obstructive sleep apnea/hypopnea syndrome (OSAHS) patients with hypertension and oropharyngeal obstruction. A retrospective cohort study was performed in 29 patients with OSAHS and hypertension, who received treatment with revised UPPP surgery. After surgery 1 month, the Apnea-hypopna index (AHI) and body mass index (BMI) significantly decreased (P < 0.05), and mini SpO(2) and mean SpO(2) increased than before (P < 0. 05), but the heart rate showed no significant difference (P > 0.05). In the meantime, compared to pretreatment, nighttime systolic SBP, nighttime diastolic DBP, morning systolic SBP, morning diastolic DBP, 24-h DBP, and 24-h SBP, decreased significantly (P < 0.05), but daytime SBP and daytime DBP showed no significant difference (P > 0.05). The results of this study indicated that the BP in the sleep apnea patients with hypertension might gradually decrease by revised UPPP surgery.
Notch Inhibitor: a Promising Carcinoma Radiosensitizer Notch inhibitor;radiotherapy;radiosensitizer; Radiotherapy is an important part of modern cancer management for many malignancies, and enhancing the radiosensitivity of tumor cells is critical for effective cancer therapies. The Notch signaling pathway plays a key role in regulation of numerous fundamental cellular processes. Further, there is accumulating evidence that dysregulated Notch activity is involved in the genesis of many human cancers. As such, Notch inhibitors are attractive therapeutic agents, although as for other anticancer agents, they exhibit significant and potential side effects. Thus, Notch inhibitors may be best used in combination with other agents or therapy. Herein, we describe evidence supporting the use of Notch inhibitors as novel and potent radiosensitizers in cancer therapy.